The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services.
Open accessAbstract
IMPORTANCE: Several randomized clinical trials have demonstrated the efficacy of preexposure prophylaxis (PrEP) in preventing human immunodeficiency virus (HIV) acquisition. Little is known about adherence to the regimen, sexual practices, and overall effectiveness when PrEP is implemented in clinics that treat sexually transmitted infections (STIs) and community-based clinics serving men who have sex with men (MSM). OBJECTIVE: To assess PrEP adherence, sexual behaviors, and the incidence of STIs and HIV infection in a cohort of MSM and transgender women initiating PrEP in the United States. DESIGN, SETTING, AND PARTICIPANTS: Demonstration project conducted from October 1, 2012, through February 10, 2015 (last date of follow-up), among 557 MSM and transgender women in 2 STI clinics in San Francisco, California, and Miami, Florida, and a community health center in Washington, DC. Data were analyzed from December 18, 2014, through August 8, 2015. INTERVENTIONS: A combination of daily, oral tenofovir disoproxil fumarate and emtricitabine was provided free of charge for 48 weeks. All participants received HIV testing, brief client-centered counseling, and clinical monitoring. MAIN OUTCOMES AND MEASURES: Concentrations of tenofovir diphosphate in dried blood spot samples, self-reported numbers of anal sex partners and episodes of condomless receptive anal sex, and incidence of STI and HIV acquisition. RESULTS: Overall, 557 participants initiated PrEP, and 437 of these (78.5%) were retained through 48 weeks. Based on the findings from the 294 participants who underwent measurement of tenofovir diphosphate levels, 80.0% to 85.6% had protective levels (consistent with ≥4 doses/wk) at follow-up visits. African American participants (56.8% of visits; P = .003) and those from the Miami site (65.1% of visits; P < .001) were less likely to have protective levels, whereas those with stable housing (86.8%; P = .02) and those reporting at least 2 condomless anal sex partners in the past 3 months (88.6%; P = .01) were more likely to have protective levels. The mean number of anal sex partners declined during follow-up from 10.9 to 9.3, whereas the proportion engaging in condomless receptive anal sex remained stable at 65.5% to 65.6%. Overall STI incidence was high (90 per 100 person-years) but did not increase over time. Two individuals became HIV infected during follow-up (HIV incidence, 0.43 [95% CI, 0.05-1.54] infections per 100 person-years); both had tenofovir diphosphate levels consistent with fewer than 2 doses/wk at seroconversion. CONCLUSIONS AND RELEVANCE: The incidence of HIV acquisition was extremely low despite a high incidence of STIs in a large US PrEP demonstration project. Adherence was higher among those participants who reported more risk behaviors. Interventions that address racial and geographic disparities and housing instability may increase the impact of PrEP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Clinical practice guidelines recommend STI screening for persons taking PrEP (80) because increased rates of STI acquisition have been described (85–87).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [85]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
The Patient Health Questionnaire-2: Validity of a Two-Item Depression Screener
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000093487.78664.3c · Cited by 6,359
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citationAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Preexposure Prophylaxis for HIV Infection among African Women
Damme, L. V., Corneli, A. L., Ahmed, K., Agot, K. E., Lombaard, J. J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R. N., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,633
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296
Grant, R. M., Anderson, P. L., McMahan, V., Liu, A., Amico, K. R., Mehrotra, M., Hosek, S., Mosquera, C., Casapía, M., Montoya, O., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70847-3 · Cited by 1,229
Regression models for ordinal responses: a review of methods and applications
Ananth, C. V. (1997) · International Journal of Epidemiology · doi:10.1093/ije/26.6.1323 · Cited by 594
Diagnoses of HIV infection in the United States and dependent areas, 2012
Siddiqi, A.-E.-A., Cohen, S. M., Johnson, A. S., Hu, X., Li, J., Patala, A., Wu, B., Guo, X., Dasari, S. R., Hall, I., et al. (2014) · Cited by 429
Detection of Acute Infections during HIV Testing in North Carolina
Pilcher, C. D., Fiscus, S. A., Nguyen, T. Q., Foust, E., Wolf, L. A., Williams, D. E., Ashby, R. M., Owen-O’Dowd, J., McPherson, J. T., Stalzer, B., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042291 · Cited by 366
Optimal recall period and response task for self-reported HIV medication adherence
Lu, M., Safren, S. A., Skolnik, P. R., Rogers, W. H., Coady, W., Hardy, H., & Wilson, I. B. (2008) · AIDS and Behavior · doi:10.1007/s10461-007-9261-4 · Cited by 361
Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion.
Bernstein, K. T., Marcus, J. L., Nieri, G., Philip, S. S., & Klausner, J. D. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181c3ef29 · Cited by 360
Donnell, D. J., Baeten, J. M., Bumpus, N. N., Brantley, J., Bangsberg, D. R., Haberer, J. E., Mujugira, A., Mugo, N., Ndase, P., Hendrix, C. W., et al. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000172 · Cited by 360
Vulnerability and unmet health care needs
Shi, L., & Stevens, G. D. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.40136.x · Cited by 322
Castillo‐Mancilla, J., Zheng, J., Rower, J. E., Meditz, A. L., Gardner, E. M., Predhomme, J. A., Fernandez, C., Langness, J. A., Kiser, J. J., Bushman, L. R., et al. (2012) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2012.0089 · Cited by 317
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention
van der Straten, A., Damme, L. V., Haberer, J. E., & Bangsberg, D. R. (2012) · AIDS · doi:10.1097/qad.0b013e3283522272 · Cited by 302
Preexposure Prophylaxis and Predicted Condom Use Among High-Risk Men Who Have Sex With Men
Golub, S. A., Kowalczyk, W. J., Lelutiu‐Weinberger, C., & Parsons, J. T. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181e19a54 · Cited by 259
Early Experiences Implementing Pre-exposure Prophylaxis (PrEP) for HIV Prevention in San Francisco
Liu, A., Cohen, S. E., Follansbee, S., Cohan, D., Weber, S., Sachdev, D. D., & Buchbinder, S. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001613 · Cited by 256
Juusola, J. L., Brandeau, M. L., Owens, D. K., & Bendavid, E. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00001 · Cited by 247
Juusola, J. L. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00004 · Cited by 244
Health Literacy Explains Racial Disparities in Diabetes Medication Adherence
Osborn, C. Y., Cavanaugh, K. L., Wallston, K. A., Kripalani, S. B., Elasy, T. A., Rothman, R. L., & White, R. O. (2011) · Journal of Health Communication · doi:10.1080/10810730.2011.604388 · Cited by 238
High Interest in Preexposure Prophylaxis Among Men Who Have Sex With Men at Risk for HIV Infection
Cohen, S. E., Vittinghoff, E., Bacon, O., Doblecki‐Lewis, S., Postle, B. S., Feaster, D. J., Matheson, T., Trainor, N., Blue, R. W., Estrada, Y. A., et al. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000479 · Cited by 188
Racial/Ethnic Disparities in ART Adherence in the United States
Simoni, J. M., Huh, D., Wilson, I. B., Shen, J., Goggin, K., Reynolds, N. R., Remien, R. H., Rosen, M. I., Bangsberg, D. R., & Liu, H. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31825db0bd · Cited by 154
Dale, S. K., Bogart, L. M., Wagner, G. J., Galván, F. H., & Klein, D. J. (2014) · Journal of Health Psychology · doi:10.1177/1359105314551950 · Cited by 144
The contexts of adherence for African Americans with high blood pressure
Rose, L. E., Kim, M. T., Himmelfarb, C. D., & Hill, M. N. (2000) · Journal of Advanced Nursing · doi:10.1046/j.1365-2648.2000.01538.x · Cited by 142
Lauffenburger, J. C., Robinson, J. G., Oramasionwu, C. U., & Fang, G. (2013) · Circulation · doi:10.1161/circulationaha.113.002658 · Cited by 142
Diagnoses of HIV infection in the United States and dependent areas, 2014
Gant, Z., Hess, K. L., Johnson, A. S., Hu, X., Li, J., Wu, B., Guo, X., Zhu, H., Liu, Y., Morgan, M. S., et al. (2015) · Cited by 121
Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence
Amico, K. R., & Stirratt, M. J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu266 · Cited by 117
Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost?
Hurt, C. B., Eron, J., & Cohen, M. S. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir684 · Cited by 101
Will Risk Compensation Accompany Pre-Exposure Prophylaxis for HIV?
Blumenthal, J. S., & Haubrich, R. (2014) · The AMA Journal of Ethic · doi:10.1001/virtualmentor.2014.16.11.stas1-1411 · Cited by 90
Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial
Amico, K. R., Marcus, J. L., McMahan, V., Liu, A., Koester, K. A., Goicochea, P., Anderson, P. L., Glidden, D. V., Guanira, J. V., & Grant, R. M. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000216 · Cited by 82
Liu, A., Glidden, D. V., Anderson, P. L., Amico, K. R., McMahan, V., Mehrotra, M., Lama, J. R., MacRae, J. D., Hinojosa, J., Montoya, O., et al. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000351 · Cited by 78
HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial
Liegler, T. J., Abdel‐Mohsen, M., Bentley, L. G., Atchison, R. E., Schmidt, T. H., Javier, J., Mehrotra, M., Eden, C., Glidden, D. V., McMahan, V., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu233 · Cited by 76
Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York
Kessler, J., Myers, J. E., Nucifora, K. A., Mensah, N., Toohey, C., Khademi, A., Cutler, B. H., & Braithwaite, R. S. (2014) · AIDS · doi:10.1097/qad.0000000000000460 · Cited by 69
Adherence to preexposure chemoprophylaxis
Amico, K. R. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3283582d4a · Cited by 68
Mimiaga, M. J., Reisner, S. L., VanDerwarker, R., Gaucher, M. J., O’Connor, C. A., Medeiros, M. S., & Safren, S. A. (2008) · AIDS Patient Care and STDs · doi:10.1089/apc.2007.0243 · Cited by 67
Trust in Primary Care Providers and Antiretroviral Adherence in an Urban HIV Clinic
Blackstock, O. J., Addison, D., Brennan, J. S., & Alao, O. A. (2012) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2012.0006 · Cited by 64
Tenofovir-Based Preexposure Prophylaxis for HIV Infection Among African Women
Marrazzo, J. M., Gita Ramjee, H., Richardson, B. A., Gomez, K., Mgodi, N. M., Nair, G., Palanee‐Phillips, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000466878.37011.6f · Cited by 62
Thames, A. D., Moizel, J., Panos, S. E., Patel, S. M., Byrd, D., Myers, H. F., Wyatt, G. E., & Hinkin, C. H. (2012) · AIDS Patient Care and STDs · doi:10.1089/apc.2012.0157 · Cited by 48
Dickson, V. V., Knafl, G. J., Wald, J. W., & Riegel, B. J. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001561 · Cited by 29
Health literacy explains racial disparities in diabetes medication adherence1)
Osborn, C., Cavanaugh, K. L., Wallston, K., Kripalani, S. B., Elasy, T., Rothman, R. L., White, R. E., & Roodbol, P. F. (2012) · Nederlands Tijdschrift voor Evidence Based Practice · doi:10.1007/s12468-012-0045-0 · Cited by 24
Molina, J., Pintado, C., Gatey, C., Ponscarme, D., Charbonneau, P., Loze, B., Rozenbaum, W., & Delaugerre, C. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-186 · Cited by 20
Preexposure Prophylaxis for HIV Infection
Steinbrook, R. (2012) · JAMA · doi:10.1001/jama.2012.9885 · Cited by 16
Preexposure Prophylaxis for HIV Infection
Siemieniuk, R. A. C., & Bogoch, I. I. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1502749 · Cited by 7
Cohen, S. E., Vittinghoff, E., Doblecki‐Lewis, S., Coleman, M. E., Bacon, O., Elion, R., Kolber, M. A., Buchbinder, S., & Liu, A. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000716 · Cited by 6
Knafl, G. J., Dickson, V. V., Riegel, B. J., et al. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/vdy0-mc78 · Cited by 1
Flagged first, then by citations
Research works printed but not linked: 6
- [4]McCormack S Dunn D Pragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD Study [Abstract 22LB] Conference on Retroviruses and Opportunistic Infections (CROI) Seattle, WA February 23-26, 2015
- [5]Molina JM Capitant C Spire B On Demand PrEP With Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial [Abstract 24LB] Conference on Retroviruses and Opportunistic Infections (CROI) Seattle, WA February 23-26, 2015 2015
- [40]Liu A Developing and Implementing a Mobile Health (mHealth) Adherence Support System for HIV-Uninfected Men who have Sex with Men (MSM) Taking Pre-Exposure Prophylaxis (PrEP): The iText Study 8th International Conference on HIV Treatment and Prevention Adherence; [AB 229] Miami, FL June 2-4, 2013
- [42]Scott H Vittinghoff E Irvin R Sex Pro: A Personalized HIV Risk Assessment Tool for Men Who Have Sex With Men [Abstract 1017] Conference on Retroviruses and Opportunistic Infections (CROI) Seattle, WA February 23-26, 2015
- [43]Vallabhaneni S Hartogensis W Sheon N Harnessing mobile health technology in HIV research: a pilot study utilizing a smartphone-based daily-diary app to collect event-level sexual activity data [Abstract TUPE358] 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention 2013 Kuala Lampur, Malaysia
- [46]Cohen SE Vittinghoff E Doblecki-Lewis S Response to “Race and the public health impact potential of PrEP in the United States” J Acquir Immune Defic Syndr 2015 PMC4558271 26049284
Cited by
Sorted by citations
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Sexually transmitted infections: challenges ahead
Unemo, M., Bradshaw, C. S., Hocking, J. S., de Vries, H. J. C., Francis, S. C., Mabey, D. C. W., Marrazzo, J. M., Sonder, G. J. B., Schwebke, J. R., Hoornenborg, E., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30310-9 · Cited by 776
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Günthard, H. F., Saag, M. S., Benson, C. A., del Rı́o, C., Eron, J. J., Gallant, J. E., Hoy, J., Mugavero, M. J., Sax, P. E., Thompson, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.8900 · Cited by 740
Molina, J.-M., Charreau, I., Spire, B., Cotte, L., Chas, J., Capitant, C., Tremblay, C., Rojas-Castro, D., Cua, E., Pasquet, A., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30089-9 · Cited by 472
Molina, J.-M., Charreau, I., Chidiac, C., Pialoux, G., Cua, E., Delaugerre, C., Capitant, C., Rojas-Castro, D., Fonsart, J., Bercot, B., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30725-9 · Cited by 449
Metadata
- Authors
- Liu, A. Y., Cohen, S. E., Vittinghoff, E., Anderson, P. L., Doblecki-Lewis, S., Bacon, O., Chege, W., Postle, B. S., Matheson, T., Amico, K. R., Liegler, T., Rawlings, M. K., Trainor, N., Blue, R. W., Estrada, Y., Coleman, M. E., Cardenas, G., Feaster, D. J., Grant, R., Philip, S. S., Elion, R., Buchbinder, S., & Kolber, M. A.
- Affiliations
- University of California, San Francisco (US)
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora
- Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida
- National Institutes of Health (US)
- DF/Net Research, Inc, Seattle, Washington
- San Francisco Department of Public Health (US)
- University of Michigan (US)
- Gilead Sciences (United States) (US)
- University of Miami (US)
- Whitman-Walker Health (US)
- Gladstone Institutes (US)
- George Washington University (US)
- Corresponding author
- Liu, Albert Y.
- ORCID
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2016-01-01
- Volume
- 176
- Issue
- 1
- Pages
- 75
- ISSN
- 2168-6106 (ISSN-L)
- PMC
- PMC5042323
- OpenAlex
- W2173821673
- Cited by
- 602
- References
- 46
- Citations by year
- 2026: 12 · 2025: 29 · 2024: 42 · 2023: 45 · 2022: 57 · 2021: 47 · 2020: 68 · 2019: 87 · 2018: 83 · 2017: 71 · 2016: 57
- FWCI
- 55.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (R01MH095628)
- National Institute of Allergy and Infectious Diseases (R01AI118575, UM1AI069496, P30AI027763, P30AI073961)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Keywords
- pre-exposure prophylaxis, HIV prevention, men who have sex with men, transgender women, tenofovir disoproxil fumarate, emtricitabine, PrEP adherence, sexually transmitted infections, sexual partners, HIV acquisition, HIV testing, community health centers, STD clinics, housing stability
- MeSH terms
- Tenofovir, Assessment of Medication Adherence, Adenine, Adolescent, Adult, Bisexuality, Chlamydia Infections, Community Health Services, District of Columbia, Female, Florida, Gonorrhea, Humans, Male, Middle Aged, Organophosphates, Prospective Studies, San Francisco, Sexual Behavior, Syphilis, HIV Infections, Drug Monitoring, Homosexuality, Male, Anti-HIV Agents, Unsafe Sex, Medication Adherence, Young Adult, Reproductive Health, Transgender Persons, Pre-Exposure Prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
